EP3808742A1 — Polymorph of selinexor
Assigned to Sandoz AG · Expires 2021-04-21 · 5y expired
What this patent protects
The present invention relates to a polymorph of selinexor and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the polymorph of selinexor of the present invention, preferably in a predetermined and/or effective amount…
USPTO Abstract
The present invention relates to a polymorph of selinexor and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the polymorph of selinexor of the present invention, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of cancers such as relapsed or refractory multiple myeloma (RRMM).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.